Paracetamol

Paracetamol belongs to the class of aniline analgesics and is structurally classified as a non-opiate, non-salicylate antipyretic agent. It is the most widely prescribed over-the-counter (OTC) medication for the management of mild-to-moderate somatic pain and fever, especially within pediatric and infant populations. Unlike traditional Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) such as ibuprofen or diclofenac, paracetamol exerts potent central antipyretic activity without causing significant peripheral anti-inflammatory effects or gastrointestinal irritation.

Our Suspensions formulation is engineered to address the specific pharmacokinetic and administration challenges of pediatric medicine. By utilizing advanced liquid dispersion matrices and premium flavoring agents, Saar Biotech ensures that the inherently bitter API is perfectly taste-masked, resulting in unmatched patient compliance.

When manufacturing high-volume, critical pediatric medications like Paracetamol, the consistency of the active pharmaceutical ingredient (API) dispersion is paramount. Saar Biotech operates out of a state-of-the-art facility located in Baddi, Himachal Pradesh.

Our specialized liquid manufacturing lines utilize high-shear micronization to reduce the Paracetamol API particle size, preventing flocculation and sedimentation. This guarantees absolute dose uniformity across the entire shelf life of the product. Furthermore, our dedicated Quality Control (QC) laboratories rigorously test every batch for heavy metals, microbial limits, and exact pH buffering, solidifying our reputation as the preferred contract manufacturing partner for top-tier pharmaceutical brands.

Paracetamol Suspension (125mg & 250mg) is indispensable in both domestic and clinical settings for the symptomatic relief of pain and pyrexia.

• Pyrexia (Fever): The primary pharmacological intervention for the rapid reduction of fever associated with viral infections, bacterial infections, and post-immunization reactions.
• Analgesia: Effective management of mild-to-moderate pain, including teething pain, toothache, headache, and sore throat.
• Post-Operative Recovery: Utilized in step-down pediatric pain management following minor surgical procedures (e.g., tonsillectomy).
• Synergistic Applications: Often co-administered with antibiotics or antihistamines to manage the symptomatic discomfort of upper respiratory tract infections (URTIs).

Central Antipyretic & Analgesic Mechanism

The precise mechanism of action of paracetamol remains a subject of intense pharmacological research; however, it is widely accepted that it acts primarily within the Central Nervous System (CNS). It reduces fever by directly acting on the hypothalamic heat-regulating center, inducing vasodilation, increased peripheral blood flow, and subsequent heat dissipation. Its analgesic effect is mediated by the elevation of the pain threshold through the inhibition of prostaglandin synthesis, specifically via the selective inhibition of the cyclooxygenase (COX) pathway, predominantly the COX-3 isoenzyme variant found within the brain and spinal cord.

Crucially, because it lacks significant COX-1 and COX-2 inhibition in peripheral tissues, it does not induce the gastric ulceration or platelet dysfunction commonly associated with standard NSAIDs.

Manufacturing Integrity

Paracetamol is prone to hydrolytic degradation and color changes if not formulated correctly. Saar Biotech utilizes a highly stabilized, aqueous-based matrix incorporating carefully selected co-solvents (such as propylene glycol or glycerin) and specific buffering systems (typically citric acid/sodium citrate) to maintain the pH within the optimal stability range (pH 5.5 to 6.5). Our proprietary manufacturing process prevents the crystallization of the API, ensuring a smooth, grit-free suspension that pours easily and adheres perfectly to dosing instruments.

Absorption & Distribution

Following oral administration, Paracetamol is rapidly and almost completely absorbed from the gastrointestinal tract, primarily in the small intestine. The rate of absorption is dependent on the rate of gastric emptying. Our specialized suspension formulation is designed to bypass the disintegration and dissolution phases required by solid tablets, resulting in a significantly faster onset of action (typically within 15 to 30 minutes).

Paracetamol is widely distributed throughout most body tissues, exhibiting minimal protein binding at therapeutic concentrations. It is extensively metabolized in the liver, primarily via glucuronidation and sulfation, and is subsequently excreted by the kidneys. The elimination half-life is approximately 1 to 3 hours, allowing for standard 4 to 6-hour dosing intervals.

Commercial Viability

For our B2B partners, Paracetamol Suspension represents a high-volume, perpetual-demand staple. It is the cornerstone of any pediatric product portfolio. By partnering with Saar Biotech, marketing companies benefit from our enormous economies of scale, allowing for highly competitive pricing structures without compromising on WHO-GMP quality. Furthermore, the dual-strength availability (125mg for infants/toddlers and 250mg for older children) allows brands to capture the entire pediatric demographic with a cohesive product line.

Saar Biotech offers comprehensive, turnkey third-party manufacturing solutions for Paracetamol Suspensions, tailored to meet the exact specifications of our B2B clients.

• Dual Strength Formulations: Available in the standard 125mg/5ml concentration for younger demographics, and the high-potency 250mg/5ml concentration (DS/Forte) for older children.
• Packaging Customizability: We provide 60ml and 100ml PET or glass bottle options, equipped with child-resistant caps (CRC) and highly accurate measuring cups or calibrated droppers.
• Flavor Engineering: Recognizing that palatability is the single biggest factor in pediatric compliance, we offer a vast library of taste-masked flavor profiles, including Strawberry, Mixed Fruit, Orange, and Mango.
• Regulatory Support: Our internal compliance team assists with CDSCO/DCGI documentation, Legal Metrology compliance for carton artworks, and the generation of comprehensive Certificates of Analysis (COA) for every dispatched batch.

To preserve the clinical efficacy and physical stability of the formulation, Paracetamol Suspension should be stored in a cool, dry environment, strictly below 30°C. It must be protected from direct sunlight, which can cause photodegradation of the flavoring and coloring agents. Do not freeze the suspension, as this may permanently alter the rheological properties of the suspending agents and cause the API to precipitate. Patients must be instructed to shake the bottle vigorously before every use to ensure complete homogenisation of the dose.

Saar Biotech’s commitment to pharmaceutical excellence is absolute. Every batch of Paracetamol Suspension is subjected to a rigid battery of analytical tests within our GLP-certified laboratories prior to release.

• HPLC Assay (Paracetamol): Validated against standard IP/BP monographs to ensure the API concentration is strictly within the 95.0% to 105.0% range.
• 4-Aminophenol Limit Test: A critical safety assay to ensure the absolute absence (or strict limitation) of 4-aminophenol, a toxic degradation product of paracetamol synthesis.
• Specific Gravity & Viscosity: Tested to guarantee the physical consistency and accurate pourability of the liquid.
• pH Verification: Ensured to be within the precise stability window to prevent hydrolysis.
• Microbial Limit Testing (MLT): Comprehensive screening confirms the absolute absence of pathogenic microorganisms, ensuring total safety for pediatric patients.

Paracetamol possesses an exceptionally favorable safety profile when administered at recommended dosages (typically 10-15 mg/kg per dose, up to 4 times a day). It is generally well-tolerated with an extremely low incidence of adverse gastrointestinal, renal, or hematological effects.

However, absolute adherence to dosing guidelines is critical. The primary risk associated with paracetamol is severe, potentially fatal hepatotoxicity resulting from acute overdose or chronic supra-therapeutic use. This occurs due to the accumulation of a toxic metabolite (NAPQI) when the liver’s glutathione conjugation pathways are saturated. It must be used with caution in patients with pre-existing hepatic impairment or severe renal dysfunction. Caregivers must be strictly counseled to avoid the simultaneous use of other paracetamol-containing OTC cold and flu remedies to prevent accidental toxicity.

For third-party manufacturing enquiries, private-label contracts, or to request pricing and packaging options for Paracetamol 125mg/250mg Oral Suspension, please use the B2B enquiry form below.